News about Global Pharma

Lupin Introduces Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03 Percent and 0.06 Percent in US

Lupin has launched its Ipratropium Bromide Nasal Solution, 0.03 percent and 0.06 percent, in the US market, offering bioequivalent alternatives to Atrovent Nasal Spray for the treatment of rhinorrhea.

Global Pharma | 04/07/2025 | By Mrinmoy Dey |  366

Sunshine Biopharma Enters Canadian Biosimilars Market with Launch of Niopeg

Niopeg is a biosimilar to Neulasta (Pegfilgrastim), a long-acting, pegylated form of recombinant human granulocyte colony-stimulating factor (filgrastim), used to reduce infection risk in cancer patients undergoing chemotherapy.

Global Pharma | 04/07/2025 | By Darshana |  243

Lincoln Pharma's New Khatraj Facility Completes Trial Run

Lincoln Pharmaceuticals Ltd has completed the trial run at its newly built manufacturing facility located at Trimul Estate in Khatraj, Gujarat.

Global Pharma | 04/07/2025 | By Manvi |  339

India, Myanmar Explore Fast-Track Pharma Approvals; MoU Likely at iPHEX 2025

India is currently a major supplier of medicines to Myanmar, meeting nearly 60% of the country’s pharmaceutical needs. The MoU will aim to expand bilateral cooperation in pharma trade and regulatory alignment.

Global Pharma | 04/07/2025 | By Darshana |  175

Alembic Pharma Acquires American Utility Therapeutics for USD 12 Million

Alembic Pharmaceuticals Inc., a wholly owned subsidiary of Alembic Pharmaceuticals Ltd., has acquired American Utility Therapeutics for USD 12 million (over INR 100 crore), strengthening its presence in the US market.

Global Pharma | 03/07/2025 | By Manvi |  216

MNCs Face Setbacks in China's Vaccine Market Amid Regulatory Crackdown and Local Competition: GlobalData

Merck recently reported a 17% decline in sales of its HPV vaccine Gardasil in China, citing increasing price pressure from domestic manufacturers and the impact of China’s ongoing anti-corruption drive in the healthcare industry.

Global Pharma | 03/07/2025 | By Darshana |  361

Biocon Biologics Receives European Commission Nod for Denosumab Biosimilars to Improve Bone Health

Biocon Biologics has received European Commission approval for its Denosumab biosimilars, Vevzuo and Evfraxy, thereby expanding access to advanced treatments for bone-related conditions across the EU.

Global Pharma | 03/07/2025 | By Mrinmoy Dey |  220

Lupin Spins Off Consumer Healthcare Arm into New Subsidiary, Appoints New CEO

Lupin noted that the move aligns with their broader strategy to establish a specialised consumer healthcare entity, with an enhanced focus on India’s rapidly growing self-care market.

Global Pharma | 02/07/2025 | By Manvi |  357

Intas Pharma Appoints Udit Sakhuja as Senior General Manager-Global New Product Launch

Prior to joining Intas, Sakhuja served at Dr. Reddy's Laboratories for over four years, where he held key leadership roles including Head of Marketing for Rheumatology and Ortho Biologics & Pain Management Portfolio, as well as Head of Marketing for NBE/NCE Innovative Oncology Assets.

Global Pharma | 02/07/2025 | By Manvi |  292

Regulus Becomes Wholly Qwned Subsidiary of Novartis

Novartis has successfully completed its acquisition of Regulus Therapeutics Inc. (Regulus), which has now become an indirect, wholly owned subsidiary of the Swiss pharmaceutical company.

Global Pharma | 02/07/2025 | By Manvi |  143